Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Citizens JMP analyst reiterated a Market Outperform rating and $6.00 price target on Nuvation Bio Inc (NYSE:NUVB) stock Friday, despite the stock’s recent 27% decline over the past week. Trading at $1.81, the stock remains below analyst consensus targets ranging from $5 to $10. The firm maintained its position following Nuvation’s detailed presentation of launch plans for its cancer treatment IBTROZI.
IBTROZI (taletrectinib), approved for adults with locally advanced or metastatic ROS1-positive NSCLC, will be priced at $29,844 per month. The company addressed questions regarding the FDA label during its presentation.
Nuvation management expressed confidence in IBTROZI’s competitive profile compared to currently FDA-approved ROS1 TKIs, citing what they described as best-in-class efficacy, duration, and safety.
Citizens JMP updated its financial model to incorporate the announced pricing structure for IBTROZI. The $6 price target remains derived from discounted cash flow analysis.
The firm’s maintained Market Outperform rating suggests continued optimism about Nuvation Bio’s market position following the IBTROZI launch details.
In other recent news, Nuvation Bio has received FDA approval for its lung cancer drug, IBTROZI (taletrectinib), intended for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This approval marks a significant step for the company as it transitions from a development-stage to a commercial-stage entity. JMP Securities maintained its Market Outperform rating on Nuvation Bio, with a price target of $6.00, despite a drop in stock price following the announcement. The firm attributes the decline to concerns over the drug’s side effect profile. Additionally, Nuvation Bio has launched a program called NuvationConnect to provide financial assistance and support for eligible patients prescribed IBTROZI. The company also announced the results of its Annual Meeting of Stockholders, where board members were elected, and executive compensation was approved. Moreover, Nuvation Bio is set to present at the 2025 American Society of Clinical Oncology annual meeting, as highlighted in a report by Citizens JMP. These developments are crucial for investors to monitor as Nuvation Bio continues to advance its presence in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.